Alnylam Pharmaceuticals Inc

NASDAQ:ALNY

144.41

-0.75 (-0.52%)

4:52:59 PM EDT: $144.41 0.00 (0.00%)

Market Cap (Intraday)	18.17B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$423.69 Million
Adjusted EPS	-$1.13

See more estimates

10-Day MA	$147.89
50-Day MA	$152.42
200-Day MA	$174.10

See more pivots

Alnylam Pharmaceuticals Inc Stock, NASDAQ:ALNY

675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142

United States of America

Phone: +1.617.551.8200

Number of Employees: 2100

http://www.alnylam.com

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.